

PsiQuantum partners with National Cancer Center Japan to accelerate drug discovery

15 March 2026 | News

Underscores the enormous potential for utility-scale quantum computing across the healthcare value chain



PsiQuantum has signed a collaborative research agreement with the National Cancer Center Japan, a leading cancer treatment and research facility, to advance applications in oncology and healthcare for utility-scale quantum computers.

This new agreement underscores the enormous potential for utility-scale quantum computing across the healthcare value chain, specifically in research and development, resource allocation, and patient outcomes in cancer treatment.

Under the newly formed collaboration, PsiQuantum will work alongside the National Cancer Center Japan to advance fault-tolerant quantum algorithm development and collaborate with the National Cancer Center Japan and other leading pharmaceutical companies in Japan in the development of clinically relevant quantum applications. The partnership will also utilize PsiQuantum's software suite, Construct—a secure, end-to-end platform for designing, analysing, and optimising algorithms for fault-tolerant quantum computing.

The research and development process for new pharmaceutical treatments is long and expensive, and current computing methods struggle to produce meaningful or reliable outcomes that expedite a treatment's time-to-market. Utility-scale quantum computers promise to deliver transformative results across the healthcare industry by simulating molecular systems with unprecedented accuracy, scale, and speed. By executing chemically accurate simulations faster, fault-tolerant quantum computers can accelerate drug discovery, lower research and development costs, and help providers tackle real-world healthcare challenges.